MUMBAI, India — India's Sun Pharmaceutical Industries is buying troubled generic drugmaker Ranbaxy Laboratories in a $4 billion all-stock transaction, the companies said Monday.
The combined company will be India's biggest pharmaceutical firm, with annual revenue estimated at $4.2 billion.
Shares of Sun Pharma rose 1.7 percent. Ranbaxy's shares were down 4.8 percent in trading on the Bombay Stock Exchange.
Ranbaxy is the leading drugmaker in India's $26 billion generic pharmaceutical industry, but it has faced penalties from U.S. regulators for years. The U.S. has banned imports of drugs from two of its factories because of concerns about quality control.
The acquisition will allow Sun Pharma to tap into Ranbaxy's strong global presence and manufacturing capabilities. The combined company will have 47 factories across five continents and operations in 65 countries, said Dilip Shanghvi, Sun Pharma's managing director.
"In high-growth emerging markets, it provides a strong platform which is highly complementary to Sun Pharma's strengths," Shanghvi said. "We see tremendous growth opportunities."
The companies said Ranbaxy shareholders will receive 0.8 shares of Sun Pharma for each share of Ranbaxy with an implied value of 457 rupees, a premium of 18 percent to Ranbaxy's average share price over 30 days. Ranbaxy shareholders are expected to own 14 percent of the new company and Ranbaxy's parent company, Japan's Daiichi Sankyo, will be the largest single shareholder.
Ranbaxy has annual revenue of about $2 billion.
The acquisition is subject to approval of shareholders of both Sun Pharma and Ranbaxy.
Anda sedang membaca artikel tentang
India's Sun Pharma buys Ranbaxy in $4 billion deal
Dengan url
http://warnakelabuabu.blogspot.com/2014/04/india-sun-pharma-buys-ranbaxy-in-4.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
India's Sun Pharma buys Ranbaxy in $4 billion deal
namun jangan lupa untuk meletakkan link
India's Sun Pharma buys Ranbaxy in $4 billion deal
sebagai sumbernya
0 komentar:
Posting Komentar